Neurocern: De-risking Dementia through Predictive Analytics and AI

Neurocern: De-risking Dementia through Predictive Analytics and AI

Written by Roger Peverelli and Reggy de Feniks - Founders The DIA Community on 11 Mar, 2019

Digital health

Neurocern’s risk management platform leverages predictive analytics and AI to meet the growing needs of insurers and the dementia population worldwide. Dementia tops every predictive model as the number one cost to economies worldwide, and it caused more deaths than prostate and breast cancer combined. Neurocern uses predictive analytics to redefine the way dementia is being diagnosed, treated and cared for.

Neurocern’s risk management platform is used to process cognitive claims and forecast reserves ahead by long term care insurance, life insurance, critical illness, and reinsurance. Considering that at least 50% of all claims are from dementia, current tools underestimate risk and do not capture the unique classification from different types of dementia which all have a distinct cost and longevity profile.

Win-win for insurers and their customers
The Neurocern platform is the only product that assesses each claim for the over 15 different types of dementia (beyond Alzheimer’s). Companies can get an unprecedented digital view of morbidity, mortality, and claims experience through implementing Neurocern in the claims process. The digital platform enables increased claims processing efficiency, data and analytics for enhanced reserve management compliance, but most importantly increased customer engagement through individualized care plans and dementia support for claimants and their families resulting in a win-win for both insurers and their customers.

Chicago-based Neurocern has partnered with some of the largest companies in the LTCI industry. They are considered a leading insurtech company by the US Society of Actuaries.

Based upon neurological clinical protocols, the Neurocern platform is far advanced from current out-dated paper-based tools that only scratch the surface when it comes to dementia. Existing products are based upon medical standards from the 1970s and only test for the 3 levels of dementia, mild, moderate, or severe.  Systemic global shortages of neurologists limit the ac">

Want to continue reading?

Sign up for our newsletter to read the full article and receive the latest news about innovation in insurance and Insurtech straight to your mailbox every week. Already signed up before?

  • Join over 20,000 other insurance executives to receive the latest innovations in insurance
  • Be the first to read our Insurtech editorials
  • Stay tuned for the latest community news
  • Get access to exclusive offers!

* required

Explore recommended articles

DIA Newsletter

Stay tuned!

Sign up to always get the latest vision
articles and insurtech news of the Digital
Insurance Agenda.

Subscribe Now


Go to top

Executive course on the impact of data on the future of insurance

Get all info here!